Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VL-PX10 in Premature Ovarian Insufficiency
NCT06072794Phase 1Suspended
- Sponsor
- Vitti Labs
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VL-PX10 in premature ovarian insufficiency (POI) and Diminished Ovarian Reserve (DOR), sponsored by Vitti Labs. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 years. Started Oct 2023; status: suspended.
02
Drugs
VL-PX10
03
Conditions
premature ovarian insufficiency (POI)Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on NCT06072794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072794.